Stock·NYSE·Healthcare
Edwards Lifesciences Corp (EW)
- Market cap
- $52.29B
- P/E
- 53.11
- Dividend yield
- None
- Street target
- $102.00median of 30 analysts
- 52-week range
- $74.66 $96.29
EW stock forecast today
Where EW stands today, and what CleaRank Financial AI makes of it.
EW at a glance
Edwards Lifesciences Corp (EW): Buy, 74/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($88.04 and $85.29).
- Earnings EW beat estimates in 6 of its last 7 quarters, yet fell the next day after 2 of those beats.
- Insiders Insiders sold $32.6M and made no open-market purchases over the last 18 months.
- Valuation P/E of 53.1 against 31.9 for the Healthcare sector: a premium to peers (+66%).
Figures as of October 27, 2026.
CleaRank Financial AI
Edwards Lifesciences Corp (EW) carries a CleaRank rating of Buy and a model score of 74/100.
Trend is the factor that lifts the score most. The price sits 6.49% above its 200-day average and 3.16% above its 50-day average, and the 50-day average is 3.23% above the 200-day. Valuation pulls the score down most: the P/E of 53.11 is 66.5% above the sector median, a premium to peers, and the P/S of 8.03 is 136.2% above the sector median. The 50-day average is $88.04 and the 200-day average is $85.29. Across the past year, the price rose 12.37%.
Only on CleaRank
Figures we compute ourselves from EW's own price, earnings and insider-filing history. Tap one to see it in context.
EW stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $90.82 is 3.2% above the 50-day simple moving average of $88.04.Price above its 200-day average ›
The price is 6.5% above the 200-day simple moving average of $85.29.50-day average above the 200-day ›
The 50-day average ($88.04) is 3.2% above the 200-day average ($85.29), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 75% of its 52-week range, between $74.66 and $96.29.
EW share price
Pick a period: each tab shows how far EW has moved over it, to the last close.
Today's trading
Where EW sits inside today's range and its 52-week range.
EW fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/4P/E below the sector median ›
The trailing P/E of 53.11 is 66.5% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 8.03 is 136.2% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $979.9M on revenue of $6.5B, a net margin of 15.0%.Beat estimates in most recent reports ›
EW beat the EPS estimate in 6 of its last 7 reports.
Key statistics
The headline figures for EW.
As of October 27, 2026, EW trades at $90.82, with a market value of $52.29B and a P/E ratio of 53.11.
What the numbers say
CleaRank Financial AI's reading of EW's valuation, growth and risks.
EW trades at a premium to peers on earnings. Its P/E of 53.11 is 66.5% above the Healthcare sector median P/E of 31.9. On sales, the price-to-sales ratio of 8.03 is 136.2% above the sector median of 3.4.
EW is growing faster than its sector. Revenue rose 13.60% in the latest quarter year on year, while the sector median was 8.1%. Profitability is strong, with a net margin of 15.0%, an operating margin of 29.84% and a return on equity of 9.18%, which sits above the sector median of 7.3%. On the balance sheet, EW carries debt-to-equity of 0.07.
Edwards Lifesciences Corp (EW) beat the estimate by 5.41% in its most recent quarterly report, released on July 23, 2026. Reported EPS of $0.78 compared with the $0.74 that analysts had forecast. Even so, the share price dropped 1.42% in the following session.
Over its last 7 reports, EW topped the estimate 6 times, but beats have not guaranteed gains: the stock fell the next day after 2 of them. Of the 3 reports before the latest, the largest reaction came after the April 23, 2026 report, which beat the estimate by 6.85% while the stock rose 5.56%. Analysts' average EPS estimate for this fiscal year is $3.00, which would be growth of 17.2%, and $3.38 for next year (growth of 12.7%).
EW's P/E of 53.11 sits 66.5% above the sector median, which marks it as a premium to peers, so any shortfall in results would be judged against a demanding bar. The price of EW typically moves 1.32% on a given day, based on the 30-day standard deviation of daily returns, and its beta against the S&P 500 is 0.86.
EW against the Healthcare sector
How EW compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: EW trades at a significant premium to sector peers (+66%), suggesting market expectations for superior growth or market position.
Return vs XLV: Since May 14, 2025, EW has gained 18.0% against a gain of 39.2% for XLV.
Performance against XLV
EW and the Healthcare sector fund over the same days.
Revenue and earnings
How much EW sells, and how much of it becomes profit.
Revenue growth: Revenue grew 11.5% in FY2025 to $6.1B, from $5.4B a year earlier.
Profit margin: The net margin was 17.6% in FY2025, down from 76.7% the year before.
Profitable: EW earned $1.1B in FY2025.
Earnings reality check
Did EW beat what analysts expected, and how did the stock react?
Earnings record: EW beat the analyst estimate in 6 of the last 7 quarters.
Market reaction: The stock fell in the first session after 2 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 23, 2026after close | $0.74 | $0.78 | +5.41% | -1.42% | +3.70% |
| Apr 23, 2026after close | $0.73 | $0.78 | +6.85% | +5.56% | +4.74% |
| Feb 10, 2026after close | $0.62 | $0.58 | -6.45% | +2.96% | +2.50% |
| Oct 30, 2025after close | $0.59 | $0.67 | +13.56% | -1.23% | -1.25% |
| Jul 24, 2025after close | $0.62 | $0.67 | +8.06% | +5.54% | +4.63% |
| Apr 23, 2025after close | $0.60 | $0.64 | +6.67% | +6.63% | +7.14% |
| Feb 11, 2025after close | $0.55 | $0.59 | +7.27% | +6.92% | +5.30% |
As of October 27, 2026, EW has beaten the analyst EPS estimate in 6 of its last 7 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on July 23, 2026, came in 5.41% above the estimate and the stock moved -1.42% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
EW AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 61.0, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 61.0 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of EW
The score, the reasoning behind it, and what could move the price next.
Edwards Lifesciences Corp (EW) is trading in an uptrend: both of its moving averages sit below the price. The price of $90.82 is 3.16% above its 50-day average of $88.04 and 6.49% above its 200-day average of $85.29. Within its 52-week range the stock sits near the top, 5.68% below the high of $96.29 and 21.64% above the low of $74.66.
The 14-day RSI of 61.0 is in the bullish zone, below the overbought line, and the MACD line is positive. The recent returns are all positive: the price rose 8.53% over the past three months, rose 10.38% over the past six months and rose 12.37% over the past year.
New analyst coverage ›
Barclays started coverage at Overweight on October 7, 2026.
Source: Analyst action, Barclays, October 7, 2026Analyst upgrade ›
Leerink Partners upgraded it to Outperform from Market Perform on July 25, 2026.
Source: Analyst action, Leerink Partners, July 25, 2026
Earnings beat, but the stock fell ›
The July 23, 2026 report beat the EPS estimate by 5.41%, and the share price fell 1.42% in the first session after it.
Source: Earnings report, July 23, 2026
- Two levels matter most for EW right now: the 52-week high of $96.29 overhead, and the 50-day SMA at $88.04 beneath the price.
- The 14-day RSI is 61.0, within the bullish zone, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- EW's share price fell 1.42% in the first session after its July 23, 2026 report. Across the last 7 reports, the company has beaten estimates in 6.
The uptrend rests on EW staying above its 50-day average at $88.04 and its 200-day average at $85.29; a close below the 50-day would be the first crack in it. On a pullback, the first level the price would meet is the 50-day SMA at $88.04.
The next level overhead for EW is its 52-week high of $96.29. With the RSI in the bullish zone, momentum is still supportive of further gains.
Technical indicators
Momentum and trend for EW, from its daily closes.
As of October 27, 2026, with EW at $90.82, its 14-day RSI is 61.0 (showing bullish momentum without being overbought), its 50-day simple moving average is $88.04 and its 200-day is $85.29.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What EW moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, EW's 1-year correlation of daily returns is +0.34 with S&P 500 (SPY), +0.28 with Nasdaq 100 (QQQ), +0.06 with Bitcoin (BTC) and +0.00 with gold (XAU).
EW price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
23 of 30 analysts rate it a buy or strong buy, 7 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $102.00 is 12.3% above the price.More buy ratings than three months ago ›
23 of 30 rate it a buy now, against 22 of 29 three months ago.
EW Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Initiates | Overweight |
| Sep 11, 2026 | BTIG | Reiterates | Buy |
| Jul 28, 2026 | UBS | Assumes | Buy |
| Jul 25, 2026 | Leerink Partners | Upgrade | Outperform |
| Jul 24, 2026 | Leerink Partners | Upgrade | Outperform |
| Jul 24, 2026 | JP Morgan | Maintains | Overweight |
As of October 27, 2026, 30 Wall Street analysts cover EW: 23 rate it a buy or strong buy, 7 a hold and 0 a sell or strong sell. Their 12-month price targets range from $84.00 to $110.00. The median EW price target is $102.00, 12.3% above the price of $90.82.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
EW trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
EW trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from EW's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much EW tends to move, against the market and on its own.
EW price history and drawdowns
EW's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.32% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 54.3%, from December 2021 to July 2024; the price is still 30.5% below that peak.Most 1-year holds ended higher ›
70% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $28,334, against $42,376 in the S&P 500 (SPY).
EW Drawdowns & Recovery
As of October 27, 2026, EW's worst peak-to-trough fall over the last 10 years with dividends reinvested was -54.3% (December 2021 to July 2024); it is still 30.5% below that peak, and 70% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into EW in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: EW trailed the S&P 500 over this period: $28,334 against $42,376.
A $10,000 investment in EW in October 2016 would be worth about $28,334 today with dividends reinvested, compared with about $42,376 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to EW, and which have not.
Strongest month, December: an average of +4.76%, up in 7 of 10 years.
Weakest month, October: an average of -3.20%, up in 4 of 9 years.
This month, October: has averaged -3.20%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, EW's strongest calendar month has been December (average +4.76%, up in 7 of 10 years) and its weakest October (average -3.20%, up in 4 of 9 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
EW stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in EW, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in EW today could grow to about $13,647 by 2030 in the base case, with a 90th-percentile outcome near $31,421 and a 10th-percentile outcome around $5,927. Projections are statistical simulations, not guarantees.
EW Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $124 for EW by 2030 in the base case, from $90.82 today (1.4x over 4 years). The 10th-percentile path ends near $53.83. These are outcomes of a Monte Carlo simulation run on EW's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $64.69 | $98.16 | $149 | |
| 2028 | $58.83 | $106 | $191 | |
| 2029 | $55.69 | $115 | $236 | |
| 2030 | $53.83 | $124 | $285 |
Method: a lognormal simulation of EW's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
EW insider trading
What the people running the company have bought and sold.
EW insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought EW shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 27, 2026, EW insiders reported 52 open-market sales worth $32.6M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 8, 2026 | Daniel J Lippis
Officer
|
Sell | 619 | $53.0K |
| Oct 8, 2026 | Daniel J Lippis
Officer
|
Option | 619 | $45.0K |
| Sep 11, 2026 | Daniel J Lippis
Officer
|
Sell | 619 | $54.2K |
| Sep 11, 2026 | Daniel J Lippis
Officer
|
Option | 619 | $45.0K |
| Aug 31, 2026 | Andrew M Dahl
Officer
|
Sell | 544 | $49.5K |
| Aug 28, 2026 | Annette Bruls
Officer
|
Sell | 2.6K | $237.9K |
| Aug 26, 2026 | Daveen Chopra
Officer
|
Sell | 31.8K | $2.9M |
| Aug 26, 2026 | Wayne Markowitz
Officer
|
Sell | 1.2K | $113.4K |
| Aug 26, 2026 | Daveen Chopra
Officer
|
Option | 31.8K | $2.3M |
| Aug 11, 2026 | Daniel J Lippis
Officer
|
Sell | 619 | $57.0K |
| Aug 11, 2026 | Daniel J Lippis
Officer
|
Option | 619 | $45.0K |
| Jul 30, 2026 | Wayne Markowitz
Officer
|
Sell | 146 | $12.6K |
| Jul 28, 2026 | Wayne Markowitz
Officer
|
Sell | 9.6K | $819.0K |
| Jul 28, 2026 | Wayne Markowitz
Officer
|
Option | 9.6K | $712.7K |
| Jul 27, 2026 | Bernard J Zovighian
Chief Executive Officer
|
Sell | 2.9K | $245.1K |
| Jul 27, 2026 | Bernard J Zovighian
Chief Executive Officer
|
Grant | 319 | - |
| Jul 10, 2026 | Daniel J Lippis
Officer
|
Sell | 619 | $56.8K |
| Jul 10, 2026 | Daniel J Lippis
Officer
|
Option | 619 | $45.0K |
| Jul 9, 2026 | Theodora Mistras
Chief Financial Officer
|
Grant | 99.9K | - |
| Jun 30, 2026 | Daniel J Lippis
Officer
|
Sell | 619 | $56.6K |
| Jun 30, 2026 | Daniel J Lippis
Officer
|
Option | 619 | $45.0K |
| Jun 17, 2026 | Bernard J Zovighian
Chief Executive Officer
|
Sell | 523 | $46.0K |
| May 29, 2026 | Andrew M Dahl
Officer
|
Sell | 567 | $48.9K |
| May 27, 2026 | Donald E Bobo Jr
Officer
|
Sell | 23.1K | $2.0M |
| May 22, 2026 | Daveen Chopra
Officer
|
Sell | 1.5K | $126.9K |
| May 18, 2026 | Daniel J Lippis
Officer
|
Sell | 620 | $50.3K |
| May 18, 2026 | Daniel J Lippis
Officer
|
Option | 620 | $45.1K |
| May 15, 2026 | Donald E Bobo Jr
Officer
|
Sell | 18.0K | $1.5M |
| May 12, 2026 | Bernard J Zovighian
Chief Executive Officer
|
Sell | 36.4K | $2.8M |
| May 12, 2026 | Bernard J Zovighian
Chief Executive Officer
|
Grant | 26.6K | - |
| May 11, 2026 | Wayne Markowitz
Officer
|
Sell | 593 | $47.3K |
| May 11, 2026 | Donald E Bobo Jr
Officer
|
Grant | 13.5K | - |
| May 11, 2026 | Daveen Chopra
Officer
|
Grant | 13.6K | - |
| May 11, 2026 | Scott B Ullem
Chief Financial Officer
|
Grant | 19.8K | - |
| May 11, 2026 | Bernard J Zovighian
Chief Executive Officer
|
Grant | 9.7K | - |
| May 11, 2026 | Bernard J Zovighian
Chief Executive Officer
|
Grant | 47.2K | - |
| May 8, 2026 | Leslie C. Davis
Director
|
Grant | 3.3K | - |
| May 8, 2026 | David T Feinberg
Director
|
Grant | 3.3K | - |
| May 8, 2026 | Kieran T. Gallahue
Director
|
Grant | 4.3K | - |
| May 8, 2026 | Paul A Laviolette
Director
|
Grant | 3.3K | - |
| May 8, 2026 | Steven R Loranger
Director
|
Grant | 4.3K | - |
| May 8, 2026 | Ramona Sequeira
Director
|
Grant | 3.3K | - |
| May 8, 2026 | Heisz Leslie Stone
Director
|
Grant | 3.3K | - |
| May 8, 2026 | Nicholas J Valeriani
Director
|
Grant | 5.1K | - |
| May 7, 2026 | Donald E Bobo Jr
Officer
|
Grant | 7.9K | - |
| May 7, 2026 | Annette Bruls
Officer
|
Grant | 6.7K | - |
| May 7, 2026 | Daveen Chopra
Officer
|
Grant | 9.7K | - |
| May 7, 2026 | Andrew M Dahl
Officer
|
Grant | 7.0K | - |
| May 7, 2026 | Daniel J Lippis
Officer
|
Grant | 7.9K | - |
| May 7, 2026 | Wayne Markowitz
Officer
|
Grant | 5.2K | - |
| May 7, 2026 | Bernard J Zovighian
Chief Executive Officer
|
Grant | 43.8K | - |
| May 5, 2026 | Scott B Ullem
Chief Financial Officer
|
Option | 13.0K | $770.3K |
| May 5, 2026 | Bernard J Zovighian
Chief Executive Officer
|
Grant | 523 | - |
| May 4, 2026 | Daniel J Lippis
Officer
|
Sell | 2.0K | $170.2K |
| May 4, 2026 | Daniel J Lippis
Officer
|
Option | 2.0K | $120.8K |
| Apr 9, 2026 | Scott B Ullem
Chief Financial Officer
|
Sell | 13.0K | $1.0M |
| Apr 9, 2026 | Scott B Ullem
Chief Financial Officer
|
Option | 13.0K | $770.3K |
| Apr 6, 2026 | Daniel J Lippis
Officer
|
Sell | 1.0K | $82.5K |
| Apr 6, 2026 | Daniel J Lippis
Officer
|
Option | 1.0K | $60.4K |
| Apr 2, 2026 | Donald E Bobo Jr
Officer
|
Sell | 22.7K | $1.8M |
| Apr 2, 2026 | Donald E Bobo Jr
Officer
|
Option | 22.7K | $1.3M |
| Mar 11, 2026 | Scott B Ullem
Chief Financial Officer
|
Sell | 13.0K | $1.1M |
| Mar 11, 2026 | Daniel J Lippis
Officer
|
Sell | 1.0K | $87.0K |
| Mar 11, 2026 | Daniel J Lippis
Officer
|
Option | 1.0K | $60.4K |
| Mar 11, 2026 | Scott B Ullem
Chief Financial Officer
|
Option | 13.0K | $770.3K |
| Mar 2, 2026 | Donald E Bobo Jr
Officer
|
Sell | 11.3K | $974.4K |
| Mar 2, 2026 | Donald E Bobo Jr
Officer
|
Option | 11.3K | $672.0K |
| Feb 25, 2026 | Donald E Bobo Jr
Officer
|
Sell | 24.0K | $2.0M |
| Feb 13, 2026 | Bernard J Zovighian
Chief Executive Officer
|
Grant | 2.9K | - |
| Feb 12, 2026 | Bernard J Zovighian
Chief Executive Officer
|
Sell | 22.4K | $1.7M |
| Feb 12, 2026 | Daniel J Lippis
Officer
|
Grant | 12.8K | - |
| Feb 12, 2026 | Bernard J Zovighian
Chief Executive Officer
|
Option | 25.4K | $1.5M |
| Jan 9, 2026 | Daniel J Lippis
Officer
|
Sell | 1.0K | $87.3K |
| Jan 9, 2026 | Daniel J Lippis
Officer
|
Option | 1.0K | $60.4K |
| Jan 6, 2026 | Donald E Bobo Jr
Officer
|
Sell | 11.3K | $971.4K |
| Jan 6, 2026 | Donald E Bobo Jr
Officer
|
Option | 11.3K | $672.0K |
| Dec 12, 2025 | Donald E Bobo Jr
Officer
|
Sell | 11.4K | $953.7K |
| Dec 12, 2025 | Heisz Leslie Stone
Director
|
Sell | 2.6K | $218.1K |
| Dec 12, 2025 | Daniel J Lippis
Officer
|
Sell | 1.0K | $85.6K |
| Dec 12, 2025 | Donald E Bobo Jr
Officer
|
Grant | 7.1K | - |
| Dec 12, 2025 | Daniel J Lippis
Officer
|
Option | 1.0K | $60.4K |
| Dec 11, 2025 | Daveen Chopra
Officer
|
Sell | 2.0K | $168.8K |
| Dec 10, 2025 | Bernard J Zovighian
Chief Executive Officer
|
Sell | 25.4K | $2.2M |
| Dec 10, 2025 | Donald E Bobo Jr
Officer
|
Sell | 11.3K | $950.6K |
| Dec 10, 2025 | Donald E Bobo Jr
Officer
|
Option | 11.3K | $672.0K |
| Dec 9, 2025 | Scott B Ullem
Chief Financial Officer
|
Sell | 7.7K | $650.4K |
| Dec 9, 2025 | Scott B Ullem
Chief Financial Officer
|
Option | 7.7K | $456.3K |
| Dec 9, 2025 | Bernard J Zovighian
Chief Executive Officer
|
Grant | 3.9K | - |
| Dec 8, 2025 | Wayne Markowitz
Officer
|
Sell | 583 | $50.1K |
| Dec 8, 2025 | Bernard J Zovighian
Chief Executive Officer
|
Option | 25.4K | $1.5M |
| Nov 13, 2025 | Andrew M Dahl
Officer
|
Grant | 1.2K | - |
| Nov 10, 2025 | Scott B Ullem
Chief Financial Officer
|
Sell | 13.0K | $1.1M |
| Nov 10, 2025 | Daniel J Lippis
Officer
|
Sell | 1.0K | $84.2K |
| Nov 10, 2025 | Daniel J Lippis
Officer
|
Option | 1.0K | $60.4K |
| Nov 10, 2025 | Scott B Ullem
Chief Financial Officer
|
Option | 13.0K | $770.3K |
| Sep 11, 2025 | Daveen Chopra
Officer
|
Grant | 3.2K | - |
| Sep 11, 2025 | Wayne Markowitz
Officer
|
Grant | 6.4K | - |
| Aug 25, 2025 | Daveen Chopra
Officer
|
Sell | 2.5K | $204.9K |
| Aug 18, 2025 | Larry L Wood
Officer
|
Sell | 9.0K | $698.7K |
| Aug 18, 2025 | Larry L Wood
Officer
|
Option | 9.0K | $530.3K |
| Jul 28, 2025 | Daniel J Lippis
Officer
|
Sell | 4.1K | $326.9K |
| Jun 16, 2025 | Larry L Wood
Officer
|
Sell | 9.0K | $673.3K |
| Jun 16, 2025 | Larry L Wood
Officer
|
Option | 9.0K | $530.3K |
| Jun 3, 2025 | Bernard J Zovighian
Chief Executive Officer
|
Sell | 17.1K | $1.3M |
| Jun 2, 2025 | Donald E Bobo Jr
Officer
|
Sell | 2.6K | $198.9K |
| May 22, 2025 | Daveen Chopra
Officer
|
Sell | 1.5K | $112.6K |
| May 16, 2025 | Bernard J Zovighian
Chief Executive Officer
|
Grant | 5.8K | - |
| May 13, 2025 | Bernard J Zovighian
Chief Executive Officer
|
Grant | 2.8K | - |
| May 9, 2025 | Scott B Ullem
Chief Financial Officer
|
Sell | 11.3K | $837.0K |
| May 9, 2025 | Daniel J Lippis
Officer
|
Sell | 330 | $24.6K |
| May 9, 2025 | Leslie C. Davis
Director
|
Grant | 3.5K | - |
| May 9, 2025 | David T Feinberg
Director
|
Grant | 3.5K | - |
| May 9, 2025 | Kieran T. Gallahue
Director
|
Grant | 4.7K | - |
| May 9, 2025 | Paul A Laviolette
Director
|
Grant | 3.5K | - |
| May 9, 2025 | Daniel J Lippis
Officer
|
Option | 330 | $14.9K |
| May 9, 2025 | Steven R Loranger
Director
|
Grant | 4.7K | - |
| May 9, 2025 | Ramona Sequeira
Director
|
Grant | 3.5K | - |
| May 9, 2025 | Heisz Leslie Stone
Director
|
Grant | 3.5K | - |
| May 9, 2025 | Scott B Ullem
Chief Financial Officer
|
Option | 11.3K | $509.4K |
| May 9, 2025 | Nicholas J Valeriani
Director
|
Grant | 5.6K | - |
Source: TwelveData, from SEC Form 4 filings
EW stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.